Christopher Stroh
Overview
Explore the profile of Christopher Stroh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
3594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oksen D, Boutmy E, Wang Y, Stroh C, Johne A, Nisbett A, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 40011191
Purpose: Mesenchymal-epithelial transition factor (MET) alterations are rare oncogenic drivers in patients with non-small cell lung cancer (NSCLC). This study characterized patients with advanced NSCLC harboring MET exon 14 (METex14)...
2.
Wu Y, Guarneri V, Voon P, Lim B, Yang J, Wislez M, et al.
Lancet Oncol
. 2024 Aug;
25(8):989-1002.
PMID: 39089305
Background: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET amplification as a mechanism of resistance to first-line osimertinib have few treatment options. Here, we report the primary analysis of...
3.
Qin S, Pan H, Blanc J, Grando V, Lim H, Chang X, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300328.
PMID: 38354329
Purpose: amplification (amp) has been reported in 1%-5% of patients with hepatocellular carcinoma (HCC) and may be sensitive to MET inhibition. Tepotinib, a selective MET inhibitor, has shown promising activity...
4.
Le X, Paz-Ares L, Meerbeeck J, Viteri S, Galvez C, Smit E, et al.
Cell Rep Med
. 2023 Nov;
4(11):101280.
PMID: 37944528
High-level MET amplification (METamp) is a primary driver in ∼1%-2% of non-small cell lung cancers (NSCLCs). Cohort B of the phase 2 VISION trial evaluates tepotinib, an oral MET inhibitor,...
5.
Albers J, Friese-Hamim M, Clark A, Schadt O, Walter-Bausch G, Stroh C, et al.
Mol Cancer Ther
. 2023 Mar;
22(7):833-843.
PMID: 36999986
The mesenchymal-epithelial transition factor (MET) proto-oncogene encodes the MET receptor tyrosine kinase. MET aberrations drive tumorigenesis in several cancer types through a variety of molecular mechanisms, including MET mutations, gene...
6.
Silginer M, Papa E, Szabo E, Vasella F, Pruschy M, Stroh C, et al.
Acta Neuropathol Commun
. 2023 Mar;
11(1):41.
PMID: 36915128
The hepatocyte growth factor (HGF)/MET signaling pathway has been proposed to be involved in the resistance to radiotherapy of glioblastoma via proinvasive and DNA damage response pathways.Here we assessed the...
7.
Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, et al.
JCO Precis Oncol
. 2021 Dec;
5.
PMID: 34957368
Materials And Methods: ex14 NSCLC cases were collected from three cohorts: the VISION trial, and data sets from Guardant360 and GenePlus. Clinicopathologic characteristics and ex14 mutation sites were analyzed and...
8.
Friese-Hamim M, Clark A, Perrin D, Crowley L, Reusch C, Bogatyrova O, et al.
Lung Cancer
. 2021 Dec;
163:77-86.
PMID: 34942492
Central nervous system-penetrant therapies with intracranial efficacy against non-small cell lung cancer (NSCLC) brain metastases are urgently needed. We report preclinical studies investigating brain penetration and intracranial activity of the...
9.
Bittoni M, Yang J, Shih J, Peled N, Smit E, Camidge D, et al.
Lung Cancer
. 2021 Jul;
159:96-106.
PMID: 34320421
Objectives: To describe characteristics, treatment and outcomes of non-small cell lung cancer (NSCLC) patients with MET alterations (MET exon 14 [METex14] skipping or MET amplification [METamp]) in real-world clinical care....
10.
Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook G, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Apr;
10(5):428-440.
PMID: 33818908
Tepotinib is a highly selective and potent MET inhibitor in development for the treatment of patients with solid tumors. Given the favorable tolerability and safety profiles up to the maximum...